Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
- Department of Thyroid and Breast Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, China
- Department of Thyroid and Breast Surgery, Ningbo Medical Center Lihuili Hospital, China
- Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, China
- Department of Thyroid and Breast Surgery, Jinhua Municipal Central Hospital, China
- Department of Thyroid and Breast Surgery, Yiwu Central Hospital, China
- Department of Breast Surgery, Ningbo Women and Children's Hospital, China
- Department of Breast Surgery, Yiwu Maternity and Children Hospital, China
- Department of Surgical Oncology, Quzhou People's Hospital, China
- Department of Breast Surgery, The First Affiliated Hospital of Ningbo University, China
- Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China
eLife Assessment
The study by Ma et al. provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial. The findings enhance the understanding of HER2-positive breast cancer. The claims are fully supported by the types of experiments that were performed.
https://doi.org/10.7554/eLife.101724.3.sa0Abstract
Background:
Approximately one-third of patients with HER2-positive breast cancer experienced recurrence within 10 years after receiving 1 year of adjuvant trastuzumab. The ExteNET study showed that 1 year of extended adjuvant neratinib after trastuzumab-based adjuvant therapy could reduce invasive disease-free survival (iDFS) events compared with placebo. This study investigated the efficacy and safety of pyrotinib, an irreversible pan-HER receptor tyrosine kinase inhibitor, after trastuzumab-based adjuvant therapy in patients with high-risk, HER2-positive early or locally advanced breast cancer.
Methods:
This multicenter phase II trial was conducted at 23 centers in China. After enrollment, patients received 1 year of extended adjuvant pyrotinib (400 mg/day), which should be initiated within 6 months after the completion of 1-year adjuvant therapy (trastuzumab alone or plus pertuzumab). The primary endpoint was 2-year iDFS rate.
Results:
Between January 2019 and February 2022, 141 eligible women were enrolled and treated. As of October 10, 2022, the median follow-up was 24 (interquartile range, 18.0–34.0) months. The 2-year iDFS rate was 94.59% (95% confidence interval [CI]: 88.97–97.38) in all patients, 94.90% (95% CI: 86.97–98.06) in patients who completed 1-year treatment, 90.32% (95% CI: 72.93–96.77) in patients who completed only 6-month treatment, 96.74% (95% CI: 87.57–99.18) in the hormone receptor (HR)-positive subgroup, 92.77% (95% CI: 83.48–96.93) in the HR-negative subgroup, 96.88% (95% CI: 79.82–99.55) in the lymph node-negative subgroup, 93.85% (95% CI: 86.81–97.20) in the lymph node-positive subgroup, 97.30% (95% CI: 82.32–99.61) in patients with adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06–97.02) in patients with adjuvant trastuzumab. The most common adverse events were diarrhea (79.4%), fatigue (36.9%), lymphocyte count decreased (36.9%), nausea (33.3%), and hand-foot syndrome (33.3%).
Conclusions:
Extended adjuvant pyrotinib administrated after trastuzumab-based adjuvant therapy showed promising efficacy in patients with high-risk HER2-positive breast cancer. The follow-up is ongoing to determine the long-term benefit.
Funding:
No external funding was received for this work.
Clinical trial number:
ClinicalTrials.gov: NCT05880927
Introduction
Worldwide, breast cancer is the most commonly diagnosed malignancy in women. Approximately 15–20% of breast cancer cases are characterized by the overexpression of human epidermal growth factor receptor 2 (HER2) (Siegel et al., 2014; Loibl and Gianni, 2017). Over the past 20 years, with the emergence of HER2-targeted agents, it has been proved that the addition of 1-year trastuzumab to adjuvant chemotherapy significantly reduces the recurrence rate and prolongs survival in patients with HER2-positive breast cancer (Perez et al., 2014; Cameron et al., 2017; Wolff et al., 2013). However, the phase III HERA study found that, despite receiving 1 year of adjuvant trastuzumab, 31% of patients with HER2-positive breast cancer experienced recurrence within 10 years (Cameron et al., 2017). In addition, the phase III APHINITY study reported a 12% recurrence rate in HER2-positive breast cancer patients with node-positive disease after receiving 1 year of adjuvant trastuzumab, pertuzumab, and chemotherapy with a median follow-up of 74 months (Piccart et al., 2021). Consequently, novel treatment approaches are warranted to extend the time to recurrence.
Currently, the efficacy of extended adjuvant therapy has only been investigated in the phase III ExteNET study. The results showed that 1 year of neratinib after trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (iDFS) in women with HER2-positive breast cancer. However, the iDFS benefit did not translate into overall survival benefit in the intention-to-treat population after 8-year follow-up, except for patients with hormone receptor (HR)-positive disease (Holmes et al., 2023; Lüftner et al., 2021; Martin et al., 2017).
Pyrotinib is an oral irreversible pan-HER receptor tyrosine kinase inhibitor (TKI), targeting epidermal growth factor receptor, HER2, and HER4 (Ma et al., 2019; Guan et al., 2023b; Xu et al., 2021). For patients with HER2-positive metastatic breast cancer, improved survival outcomes were shown in the pyrotinib group when compared with the control group in the phase III PHOEBE and PHILA studies (Ma et al., 2023; Wu et al., 2022). Additionally, results from the phase III PHEDRA trial demonstrated clinical benefits of pyrotinib plus trastuzumab and docetaxel for patients with HER2-positive early or locally advanced breast cancer in the neoadjuvant setting (Chan et al., 2016).
In the present PERSIST study, our objective was to assess the efficacy and safety of administering extended adjuvant pyrotinib treatment following trastuzumab-based adjuvant therapy in patients with high-risk, HER2-positive early or locally advanced breast cancer. This report presents the efficacy and safety results with a median follow-up of 2 years, while longer follow-up is still ongoing.
Methods
Study design and participants
This multicenter, single-arm, investigator-initiated, phase II exploratory study was conducted at 23 sites in China. The study protocol was approved by the institutional ethics committee of Taizhou Hospital of Zhejiang Province and all other participating centers, and the trial was performed in accordance with the 2013 Declaration of Helsinki. This trial was registered at https://clinicaltrials.gov/ (NCT05880927). Written informed consent was obtained from all patients before study enrollment.
Participants were eligible if they were women aged 18–75 years with high-risk, HER2-positive (immunohistochemistry 3+, or 2+ with gene amplification by fluorescence in situ hybridization) early or locally advanced invasive breast cancer; had previously completed 1 year of adjuvant therapy with either trastuzumab or trastuzumab plus pertuzumab within 6 months before enrollment; had an Eastern Cooperative Oncology Group performance status of 0 or 1; had known HR status; and had adequate bone marrow, hepatic, renal, and cardiac functions.
High-risk patients were defined as those meeting one of the following criteria: N stage ≥1; T stage ≥2; absence of pathological complete response (pCR) after neoadjuvant therapy; presence of pCR after neoadjuvant therapy but with tumor size ≥5 cm or N stage ≥2; tumor size <2 cm but with high Ki-67 level or histologic grade 3. Clinical and pathological stage was assessed according to the eighth edition of American Joint Committee on Cancer tumor-node-metastasis staging system. The expression of Ki-67 was categorized as low (<20%) and high (≥20%) based on the ratio of positive cells to all tumor cells in 10 high-power fields.
The main exclusion criteria were bilateral breast cancer, inflammatory breast cancer, previous participation in other clinical trials involving anticancer therapy, allergies to the drug components in this protocol, history of immunodeficiency diseases, inability to swallow, and pregnancy or lactation.
Procedure
Pyrotinib 400 mg was administrated orally once daily within 6 months of completing trastuzumab-based adjuvant therapy. Concurrent adjuvant endocrine therapy for HR-positive disease was recommended.
Treatment duration was 12 months unless intolerable adverse events, disease recurrence, death, or consent withdrawal occurred.
Outcomes and assessment
The primary endpoint was iDFS rate at 2 years. IDFS was defined as time from the initiation of pyrotinib treatment to invasive ipsilateral tumor recurrence, invasive contralateral breast cancer, local or regional invasive recurrence, distant recurrence, or death from any cause. The secondary endpoint was safety profile, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Patients were followed every 3 months for the first 2 years. The follow-up assessments included physical examination, Eastern Cooperative Oncology Group performance status, complete blood count, blood chemistry analysis, 12-lead electro-cardiogram, recording of adverse events, concomitant medications, and ultrasound. Computed tomography and bone scans may be conducted if clinically indicated.
Statistical analysis
Based on the previous ExteNET trial (Burstein et al., 2021), the 2-year iDFS rate was assumed as 91% in the present study. To restrain the width of 2-sided 95% confidence interval (CI) to no more than 0.1, 126 patients were required. Considering a dropout rate of 10%, a total of 140 participants were recruited.
Continuous data were presented as median (range or interquartile range), while categorical data were presented as frequency (percentage). IDFS was estimated using the Kaplan–Meier method, and the corresponding 95% CI was estimated using the Brookmeyer–Crowley method. Efficacy analysis was performed in the full analysis set, which included all patients who received at least one dose of study drug. Safety analysis was performed in the safety set, defined as all patients who received at least one dose of the study drug and underwent at least one safety assessment.
Results
Baseline characteristics
Between January 2019 and February 2022, a total of 141 eligible women were enrolled in the study and received pyrotinib. All these patients were included in the full analysis set and safety set. The median age was 50 years (range, 25–72). Of the 141 patients, 107 (75.9%) patients had node-positive disease, and 64 (45.4%) had HR-positive disease. Detailed baseline characteristics are summarized in Table 1.
Table 1
Baseline characteristics of patients in the full analysis set.
| Variables | All (n = 141) |
|---|---|
| Age (years), median (range) | 50 (25–72) |
| T stage, n (%) | |
| T1 | 43 (30.5%) |
| T2 | 83 (58.9%) |
| T3 | 11 (7.8%) |
| T4 | 2 (1.4%) |
| Unable to determine | 2 (1.4%) |
| Nodal status, n (%) | |
| Negative | 34 (24.1%) |
| 1–3 positive nodes | 49 (34.8%) |
| >3 positive nodes | 58 (41.1%) |
| Hormone receptor status, n (%) | |
| Negative (ER and PR negative) | 77 (54.6%) |
| Positive (ER positive, PR positive, or both) | 64 (45.4%) |
| Ki-67, n (%) | |
| ≥20% | 119 (84.4%) |
| <20% | 22 (15.6%) |
| Previous neoadjuvant therapy, n (%) | 26 (17.7%) |
| Previous adjuvant therapy, n (%) | |
| Trastuzumab | 92 (65.2%) |
| Trastuzumab plus pertuzumab | 49 (34.8%) |
-
Tumors were assessed as being ER or PR positive with a threshold of 1%.
-
ER, estrogen receptor; PR, progesterone receptor.
In terms of treatment duration, 11 patients discontinued their treatment due to adverse events, while 38 patients had a treatment duration of less than or equal to 6 months due to the COVID-19 pandemic or personal reasons. A total of 92 and 31 patients completed 1-year and 6-month treatment of extended adjuvant pyrotinib, respectively (Figure 1).
Figure 1
Study flowchart.
Efficacy
As of October 10, 2022, the median follow-up duration was 24 (interquartile range, 18.0–34.0) months. Of the 141 patients, seven patients experienced iDFS events, including one local recurrence, three brain metastases, two lung metastases, and one death due to distant metastasis. The 2-year iDFS rate was 94.59% (95% CI: 88.97–97.38; Figure 2).
Figure 2
Kaplan–Meier estimates of invasive disease-free survival in the full analysis set.
Subgroup analyses showed that the 2-year iDFS rate was 94.90% (95% CI: 86.97–98.06) in the 1-year treatment subgroup and 90.32% (95% CI: 72.93–96.77) in the 6-month treatment subgroup (Figure 3A). Concerning HR status, the 2-year iDFS rate was 96.74% (95% CI: 87.57–99.18) in patients with HR-positive breast cancer and 92.77% (95% CI: 83.48–96.93) in patients with HR-negative breast cancer (Figure 3B). In terms of lymph node status, the 2-year iDFS rate was 96.88% (95% CI: 79.82–99.55) in patients with lymph node-negative breast cancer and 93.85% (95% CI: 86.81–97.20) in patients with lymph node-positive breast cancer (Figure 3C). Regarding trastuzumab-based adjuvant regimen, the 2-year iDFS rate was 97.30% (95% CI: 82.32–99.61) in patients who received adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06–97.02) in patients who received adjuvant trastuzumab (Figure 3D).
Figure 3
Invasive disease-free survival in different subgroups.
Kaplan–Meier curves for invasive disease-free survival in (A) patients who received 6-month (n = 31) and 1-year pyrotinib treatment (n = 92), (B) patients with hormone receptor-positive breast …
Safety
The most frequently reported treatment-emergent adverse event was diarrhea (112 [79.4%]), followed by fatigue (52 [36.9%]), lymphocyte count decreased (52 [36.9%]), nausea (47 [33.3%]), and hand-foot syndrome (47 [33.3%]). Forty-three patients (30.5%) experienced grade 3 diarrhea, while no grade 4 or higher adverse events was reported (Table 2). Treatment discontinuation occurred in 11 (7.8%) patients, due to grade 3 diarrhea (n = 8), grade 3 hand-foot syndrome (n = 1), and intolerance (n = 2). In addition, 16 patients had dose reduction because of adverse events.
Table 2
Treatment-emergent adverse events occurring in at least 10% of the patients.
| Events, n (%) | All (n = 141) | |
|---|---|---|
| Any grade | Grade 3 | |
| Diarrhea | 112 (79.4%) | 43 (30.5%) |
| Fatigue | 52 (36.9%) | 0 |
| Lymphocyte count decreased | 52 (36.9%) | 0 |
| Nausea | 47 (33.3%) | 0 |
| Hand-foot syndrome | 47 (33.3%) | 1 (0.7%) |
| Hyperuricemia | 33 (23.4%) | 0 |
| White blood cell count decreased | 26 (18.4%) | 0 |
| Dizziness | 26 (18.4%) | 0 |
| Anemia | 24 (17.0%) | 0 |
| Vomiting | 22 (15.6%) | 0 |
| Headache | 19 (13.5%) | 0 |
| Creatinine increased | 17 (12.1%) | 0 |
| Neutrophil count decreased | 16 (11.3%) | 0 |
Discussion
To the best of our knowledge, this multicenter phase II study is the first prospective study to explore the efficacy and safety of extended adjuvant pyrotinib after trastuzumab-based adjuvant therapy in patients with high-risk HER2-positive breast cancer. Furthermore, while the ExteNET study only included patients who received neoadjuvant or adjuvant trastuzumab, over one-third of the patients in our study had received dual anti-HER2 blockade with trastuzumab and pertuzumab, making it more clinically applicable to current clinical practice (Bevers et al., 2023). In China, pertuzumab was approved for the treatment of HER2-positive breast cancer in the adjuvant setting in 2018, and has been covered by medical insurance since 2020. The PERSIST study started in 2019, thus the proportion of eligible patients who received trastuzumab and pertuzumab in our study was relatively high. In addition, we conducted subgroup analyses to explore the differences in the efficacy of extended adjuvant pyrotinib across different prior adjuvant regimens, including trastuzumab plus pertuzumab or trastuzumab alone, and different treatment durations.
Currently, only neratinib has been approved by Food and Drug Administration in the extended adjuvant setting for patients with HER2-positive early or locally advanced breast cancer. In the 2023 National Comprehensive Cancer Network guidelines, it has been recommended for the treatment of high-risk, HR-positive, HER2-positive breast cancer (Nahta and O’Regan, 2012). In the ExteNET study, 1-year neratinib treatment after adjuvant trastuzumab significantly improved iDFS in patients with HER2-positive breast cancer, with a 2-year iDFS rate of 93.9% in the neratinib group and 91.6% in the placebo group (Martin et al., 2017; Burstein et al., 2021). In our study, the 2-year iDFS rate was 94.59%, comparable to that in the ExteNET study.
In terms of subgroup analyses, the HR-positive group seemed to show a numerically higher 2-year iDFS rate than the HR-negative group (96.74% vs 92.77%). Consistently, similar results were observed in the ExteNET study. The underlying mechanism may involve cross-talk between HR and HER2 pathways (Pegram et al., 2023; Sudhan et al., 2019). Preclinical studies have shown that in estrogen receptor+/HER2+ cell lines, neratinib treatment also suppresses the activity of estrogen reporter (Hu et al., 2023). In the present study, adjuvant endocrine therapy was recommended for patients with HR-positive disease when treated with pyrotinib, which may generate synergistic effects (Zhang et al., 2022; Pivot et al., 2019).
Regarding duration of treatment, the results showed that the 2-year iDFS rate was numerically higher with 1-year pyrotinib treatment (94.90%) versus 6-month pyrotinib treatment (90.32%). In the adjuvant setting, a phase III PHARE trial compared 1-year adjuvant trastuzumab with 6-month treatment, and the non-inferiority was not achieved for disease-free survival. Therefore, 1-year adjuvant trastuzumab remained the standard treatment (von Minckwitz et al., 2017). Further studies are warranted to find the optimal duration of extended adjuvant pyrotinib.
Adjuvant treatment regimens before extended adjuvant treatment may also be associated with iDFS. In the present study, the 2-year iDFS rate was 93.48% and 97.30% in the trastuzumab subgroup and trastuzumab plus pertuzumab subgroup, respectively. The APHINITY study demonstrated a significantly improved iDFS with adjuvant trastuzumab plus pertuzumab than with adjuvant trastuzumab alone (von Minckwitz et al., 2019). Therefore, the iDFS benefits may last and affect the results in the extended adjuvant period.
None of the patients in the PERSIST study received trastuzumab emtansine (T-DM1), which is now a standard of care for HER2-positive patients with residual cancer after neoadjuvant therapy based on the phase III KATHERINE trial (Liang et al., 2024). Since T-DM1 was approved in China in 2020 and was not covered by medical insurance until 2023, it has not been widely used in clinical practice. Recently, a real-world study showed that patients with metastatic breast cancer could benefit from pyrotinib-based therapy after T-DM1 treatment (Shyam Sunder et al., 2023). Therefore, patients with high-risk breast cancer may also benefit from extended adjuvant pyrotinib after being treated with T-DM1 in the adjuvant setting, which needs further investigation.
Regarding adverse events, diarrhea was the major safety concern in the present study, leading to treatment discontinuation in eight patients. This adverse event as well as vomiting and nausea are TKI-related common adverse events. The underlying mechanisms of these adverse events are not clear yet, and the mainstream hypothesis is that the growth and healing of epithelial cells in gastrointestinal tract are inhibited by TKIs (Secombe et al., 2020; Guan et al., 2023a). In the present study, 43 (30.5%) patients experienced grade 3 diarrhea, which were consistent with previous studies of pyrotinib (Guan et al., 2023b; Fang et al., 2022). Noteworthy, primary prophylaxis was not mandatory in this PERSIST trial. Currently, loperamide hydrochloride has been found to significantly alleviate symptoms of diarrhea and reduce diarrhea-related treatment discontinuation. It has been recommended for patients treated with pyrotinib (Zheng et al., 2023). In the PANDORA trial of pyrotinib plus docetaxel, the incidence of diarrhea was significantly lower in the loperamide prophylaxis group (8.9%) compared with the non-prophylaxis group (38.2%) (Barcenas et al., 2020). In the CONTROL trial, all cohorts that received loperamide prophylaxis and the dose escalation cohort of neratinib exhibited lower grade 3 diarrhea rates and fewer instances of diarrhea-related treatment discontinuation compared with ExteNET (Barcenas et al., 2020). The above two studies indicated that pyrotinib-related diarrhea could be controlled with prophylaxis or dose modification.
There are several limitations in the present study. First, our study was a single-arm study without control group. Second, patients who received T-DM1 therapy in the adjuvant setting were not enrolled. Third, 27.0% of patients did not complete 1-year extended adjuvant pyrotinib due to COVID-19 pandemic or personal reasons. Finally, the follow-up time was short. A phase III clinical trial (NCT03980054) of extended adjuvant pyrotinib in patients with high-risk HER2-positive breast cancer is ongoing, which will further demonstrate the efficacy of extended adjuvant TKI and bring new hope for patients with high-risk HER2-positive breast cancer.
Conclusions
Our study suggests the potential of extended adjuvant pyrotinib in patients with high-risk HER2-positive early or locally advanced breast cancer after trastuzumab-based adjuvant therapy. The follow-up is ongoing to determine the long-term benefit of extended adjuvant pyrotinib.
Clinical trial registration number
This trial was registered at https://clinicaltrials.gov/ (NCT05880927).
Data availability
All data used in the manuscript (with all private patient information removed) is included with the article as Source Data File 1. This file contains all the data used for the tables and for generating the graphs and charts.
References
-
NCCN guidelines insights: breast cancer screening and diagnosis, version 1.2023Journal of the National Comprehensive Cancer Network 21:900–909.https://doi.org/10.6004/jnccn.2023.0046
-
Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patientsAnnals of Palliative Medicine 11:210–216.https://doi.org/10.21037/apm-21-3978
-
Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancerSignal Transduction and Targeted Therapy 8:118.https://doi.org/10.1038/s41392-023-01322-w
-
Blair HA: pyrotinib: first global approval. drugsThe Lancet Oncology 78:1688–1700.https://doi.org/10.1007/s40265-018-0997-0
-
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancersBreast Cancer Research and Treatment 135:39–48.https://doi.org/10.1007/s10549-012-2067-8
-
Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-upJournal of Clinical Oncology 39:1448–1457.https://doi.org/10.1200/JCO.20.01204
-
Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiomeIntegrative Cancer Therapies 19:1534735420928493.https://doi.org/10.1177/1534735420928493
-
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical managementSignal Transduction and Targeted Therapy 8:262.https://doi.org/10.1038/s41392-023-01469-6
-
Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancerThe New England Journal of Medicine 377:122–131.https://doi.org/10.1056/NEJMoa1703643
-
Trastuzumab emtansine for residual invasive HER2-positive breast cancerThe New England Journal of Medicine 380:617–628.https://doi.org/10.1056/NEJMoa1814017
Article and author information
Author details
Funding
No external funding was received for this work.
Acknowledgements
We thank all the patients who participated in this trial and their families, as well as the investigators and staff. We thank Yan Luo (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co, Ltd) for data interpretation and Yunning Yang (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co, Ltd) for medical writing assistance according to Good Publication Practice Guidelines.
Ethics
registration NCT05880927.
The study protocol was approved by the institutional ethics committee of Taizhou Hospital of Zhejiang Province and all other participating centers.
Version history
- Preprint posted:
- Sent for peer review:
- Reviewed Preprint version 1:
- Reviewed Preprint version 2:
- Version of Record published:
Cite all versions
You can cite all versions using the DOI https://doi.org/10.7554/eLife.101724. This DOI represents all versions, and will always resolve to the latest one.
Copyright
© 2024, Cao, Ma, Wu et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 283
- views
-
- 41
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Further reading
-
- Medicine
- Neuroscience
C-C chemokine receptor type 5 (CCR5) antagonists may improve both acute stroke outcome and long-term recovery. Despite their evaluation in ongoing clinical trials, gaps remain in the evidence supporting their use. With a panel of patients with lived experiences of stroke, we performed a systematic review of animal models of stroke that administered a CCR5 antagonist and assessed infarct size or behavioural outcomes. MEDLINE, Web of Science, and Embase were searched. Article screening and data extraction were completed in duplicate. We pooled outcomes using random effects meta-analyses. We assessed risk of bias using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool and alignment with the Stroke Treatment Academic Industry Roundtable (STAIR) and Stroke Recovery and Rehabilitation Roundtable (SRRR) recommendations. Five studies representing 10 experiments were included. CCR5 antagonists reduced infarct volume (standard mean difference −1.02; 95% confidence interval −1.58 to −0.46) when compared to stroke-only controls. Varied timing of CCR5 administration (pre- or post-stroke induction) produced similar benefit. CCR5 antagonists significantly improved 11 of 16 behavioural outcomes reported. High risk of bias was present in all studies and critical knowledge gaps in the preclinical evidence were identified using STAIR/SRRR. CCR5 antagonists demonstrate promise; however, rigorously designed preclinical studies that better align with STAIR/SRRR recommendations and downstream clinical trials are warranted. Prospective Register of Systematic Reviews (PROSPERO CRD42023393438).
-
- Immunology and Inflammation
- Medicine
Preeclampsia (PE), a major cause of maternal and perinatal mortality with highly heterogeneous causes and symptoms, is usually complicated by gestational diabetes mellitus (GDM). However, a comprehensive understanding of the immune microenvironment in the placenta of PE and the differences between PE and GDM is still lacking. In this study, cytometry by time of flight indicated that the frequencies of memory-like Th17 cells (CD45RA−CCR7+IL-17A+CD4+), memory-like CD8+ T cells (CD38+CXCR3−CCR7+Helios−CD127−CD8+) and pro-inflam Macs (CD206−CD163−CD38midCD107alowCD86midHLA-DRmidCD14+) were increased, while the frequencies of anti-inflam Macs (CD206+CD163−CD86midCD33+HLA-DR+CD14+) and granulocyte myeloid-derived suppressor cells (gMDSCs, CD11b+CD15hiHLA-DRlow) were decreased in the placenta of PE compared with that of normal pregnancy (NP), but not in that of GDM or GDM&PE. The pro-inflam Macs were positively correlated with memory-like Th17 cells and memory-like CD8+ T cells but negatively correlated with gMDSCs. Single-cell RNA sequencing revealed that transferring the F4/80+CD206− pro-inflam Macs with a Folr2+Ccl7+Ccl8+C1qa+C1qb+C1qc+ phenotype from the uterus of PE mice to normal pregnant mice induced the production of memory-like IL-17a+Rora+Il1r1+TNF+Cxcr6+S100a4+CD44+ Th17 cells via IGF1–IGF1R, which contributed to the development and recurrence of PE. Pro-inflam Macs also induced the production of memory-like CD8+ T cells but inhibited the production of Ly6g+S100a8+S100a9+Retnlg+Wfdc21+ gMDSCs at the maternal–fetal interface, leading to PE-like symptoms in mice. In conclusion, this study revealed the PE-specific immune cell network, which was regulated by pro-inflam Macs, providing new ideas about the pathogenesis of PE.
